For Canadian researchers, the operating reality in 2026 is a tightening Health Canada enforcement environment combined with a demanding documentation standard for any laboratory material
Because it involves peptide handling and, in many cases, injectable use, it should not be approached casually
On 23-24 July 2026, the US Food and Drug Administrations Pharmacy Compounding Advisory Committee recommended that six of seven peptides it assessed (BPC-157, KPV, TB-500,MOTS-c, epitalon and semax) be considered for inclusion on the section 503A Bulks List, potentially permitting their use in patient-specific compounded preparations.[2,7] The votes were close and advisory
The variant used as the basis for this article contains GHK-Cu 25 mg, TB-500 10 mg, BPC-157 10 mg and KPV 10 mg, totaling 55 mg
each 10 mg vial provides 24 days of material
The Philippine cohort used 30 mL daily